Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AG-120 (ivosidenib) plus azacitidine vs azacitidine alone in previously untreated IDH1-mutated AML
2024-514309-73-00Phase 3Authorised
- Sponsor
- Servier
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 17
01
Overview
Phase 3, randomised, double-blind trial in acute myeloid leukemia (AML) comparing AG-120 + azacitidine with Placebo + azacitidine (2 arms). Primary endpoint: Event-free survival. Planned start Nov 2024; status: authorised.
02
Drugs
ivosidenib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2024-514309-73-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514309-73-00.